<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Nguyen, Quan Dong</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Intravitreal Aflibercept Has Long-Term Benefits in Treatment of DME</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-10</style></pages><abstract><style  face="normal" font="default" size="100%">This article describes the 2-year outcomes of the Intravitreal Alfibercept Injection in Vision Impairment Due to DME [VIVID; NCT01331681] trial as well as the Study of Intravitreal Administration of VEGF Trap-Eye (BAY86-5321) in Patients With Diabetic Macular Edema [VISTA; NCT01363440]. VIVID and VISTA are both phase III, randomized, double-blind global studies in which intravitreal aflibercept was injected to treat diabetic macular edema.</style></abstract><number><style face="normal" font="default" size="100%">43</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>